During the pandemic, Research Partnership has been staying abreast of ongoing developments in the pharmaceutical, market research and market access industries, providing commentary on COVID-19, and running both ad hoc and syndicated studies investigating the impact of the virus on healthcare provision and the pharmaceutical industry.
Here are links to our current services and resources:
Innovations booming during COVID-19 and how to adopt them successfully
How will COVID-19 affect uptake of vaccinations against other diseases?
Fake news pandemic: The rise of healthcare misinformation in the age of COVID-19
The race to secure a SARS CoV-2 vaccine: Big promises linked to big(ger) deals
COVID-19: Accelerating digitalisation in emerging markets
The unprecedented challenge of pricing a coronavirus vaccine
How will COVID-19 affect the financing of healthcare provision across the US?
The impact of COVID-19 on rare disease patients in the EU
COVID-19 and artificial intelligence
COVID-19 and behavioural science
How we conducted conference research to understand physician reactions to abstracts presented in a virtual setting
How we conducted rare disease patient research during the COVID-19 lockdown in China
Keeping up with the Coronavirus: Monitoring the impact of COVID-19 on the market access landscape
Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19
Digital #MRX: How to use the latest technology to conduct market research in the age of COVID-19 and beyond
Continuity of business under COVID-19
Research Partnership is firmly committed to the highest quality market research and consulting services, while protecting the health and wellbeing of our staff, suppliers and clients. We have comprehensive business continuity plans and policies in place to ensure we can continue to work effectively during the pandemic.
Our 200 employees working across 6 global offices are now working effectively from home. Market research studies that were originally going to be conducted face-to-face interviews have been moved to telephone or video. As we move forward, we are successfully able to utilise a full range of digital methodologies.
Feasibility research conducted amongst HCPs by our partners, as well as our own monitoring, suggests that, whilst some projects are taking longer than usual, market research can continue amongst those who are willing and able to participate.
Our senior management monitor the situation on a daily basis. We have initiated the following working practices:
Compliance and GDPR
We continue to comply with GDPR while conducting MR and during other company activities. We take a sensible, empathetic approach, providing key privacy information to our data subjects, including their rights to be informed and to be able to withdraw at any time. Consent is obtained through clearly written contracts which references the current COVID-19 climate and details how personal data will remain confidential.
Specific methodologies and materials include the provision for GDPR. For example, if the client wishes to view an interview live or requests the recording afterwards, we ensure the necessary safeguards are in place. This may include distorting audio or pixelating images and/or gaining consent from the respondent if the interview is not anonymous. If transfer of personal data needs to occur, respondents are informed of the commissioning pharmaceutical company, usually at the end of the interview (if the respondent agrees), to avoid bias and ensure answers remain scientifically valid.
It appears we will be working from home for some time. Our employees are regularly reminded of their data protection responsibilities. No documents containing personal information should be left lying around the home and finished documentation must be securely shredded. When printing, we ask that personal information is redacted where possible.
If you have any immediate questions or require any further information, please contact your Account Director in the first instance, otherwise use the contact form below.